Connect Biopharma Holdings Limited
CNTB
$2.55
$0.010.39%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 50.28% | -99.10% | -99.75% | -96.99% | -91.85% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 50.28% | -99.10% | -99.75% | -96.99% | -91.85% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 50.28% | -99.10% | -99.75% | -96.99% | -91.85% |
| SG&A Expenses | 6.05% | 10.94% | 16.70% | 16.44% | 13.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.27% | 50.72% | 28.38% | 0.22% | -15.49% |
| Operating Income | -51.31% | -266.62% | -201.65% | -89.86% | -39.86% |
| Income Before Tax | -53.97% | -279.81% | -258.86% | -118.82% | -76.17% |
| Income Tax Expenses | -27.94% | -22.67% | -11.66% | 90.34% | 134.48% |
| Earnings from Continuing Operations | -53.47% | -275.46% | -255.00% | -118.64% | -76.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -53.47% | -275.46% | -255.00% | -118.64% | -76.44% |
| EBIT | -51.31% | -266.62% | -201.65% | -89.86% | -39.86% |
| EBITDA | -52.05% | -276.73% | -208.57% | -92.12% | -40.68% |
| EPS Basic | -47.32% | -271.44% | -252.26% | -117.09% | -75.38% |
| Normalized Basic EPS | -54.03% | -363.51% | -349.57% | -153.42% | -77.81% |
| EPS Diluted | -47.32% | -271.44% | -252.26% | -116.14% | -74.02% |
| Normalized Diluted EPS | -54.03% | -358.48% | -344.09% | -151.46% | -76.71% |
| Average Basic Shares Outstanding | 4.43% | 1.23% | 0.81% | 0.57% | 0.43% |
| Average Diluted Shares Outstanding | 4.43% | 0.99% | 0.57% | 0.33% | 0.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |